Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales. He exercised stock options to acquire 10,000 shares of Common Stock at $5.35 per share, then sold 10,000 shares in two open-market transactions.
The sales covered 2,087 shares at a weighted-average price of about $57.76 and 7,913 shares at a weighted-average price of about $57.16, with actual prices ranging from $56.595 to $58.32, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. Following these transactions, he holds 104,395 shares directly and 61,850 shares indirectly through ALG 2025 GRAT Holdings LLC.
Vaxcyte, Inc. chief operating officer Jim Wassil reported a set of transactions in the company’s common stock. He sold a total of 2,250 shares in open-market trades at weighted-average prices around the mid‑$50s per share under a Rule 10b5-1 trading plan adopted on December 9, 2025. On the same date, he exercised a stock option to acquire 516 shares at an exercise price of $5.35 per share, reducing his remaining option position. After these trades, he continues to hold a substantial stake of more than 150,000 shares of common stock, along with tens of thousands of remaining stock options.
PCVX affiliate filed a Form 144 reporting a proposed sale of 10,000 common shares. The filing lists the sale method as an Exercise of Stock Options with cash consideration on 07/06/2026. The filing also records a prior sale of 10,000 common shares on 06/18/2026 for $530,000.
PCVX reported proposed affiliate sales and recent dispositions by James Wassil.
The filing lists three prior open-market dispositions by James Wassil of 2,250 shares each on 04/01/2026, 05/01/2026, and 06/01/2026 with proceeds of $131,475.60, $127,870.65, and $111,416.62, respectively. The form also lists securities to be sold or issued to the issuer: 724 RSUs vesting 09/02/2025, 1,010 RSUs vesting 09/07/2025, and 516 shares from an exercise of stock options on 07/01/2026 (cash exercise).
Vaxcyte, Inc. director and CEO Grant Pickering reported open-market sales of 24,237 shares of Common Stock on June 26, 2026. The transactions included sales by trusts for the benefit of his son and daughter, as well as shares held directly. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026. After the direct sales, he held 468,020 shares directly.
PCVX Form 144 notice listing proposed resales of Common stock through UBS Financial Services and documenting recent affiliate sales.
The filing lists securities by grant type and vest date with quantities (for example: RSU Vest 03/02/2025 — 2,410 shares; Founder Shares 12/09/2013 — 2,000 shares; other RSU vests of 7,752 and 12,075). The filing also reports sales during the past three months: Grant Pickering sold 22,461 shares on 06/18/2026 for $1,179,204.75; The Claire Pickering 2020 Delaware Trust sold 1,000 shares for $52,500.00; and The Benjamin Pickering 2020 Delaware Trust sold 1,000 shares for $52,500.00, all on 06/18/2026.
Vaxcyte, Inc. director Moncef Slaoui reported receiving a new stock option grant covering 26,061 shares of common stock. The option has an exercise price of $52.11 per share and expires on June 22, 2036.
The award was granted at no cost and is classified as a compensation-related grant, not an open‑market purchase or sale. According to the vesting terms, one‑third of the option will vest on June 17, 2027, with the remaining portion vesting in equal monthly installments over the following 24 months, contingent on his continued service with the company.
Vaxcyte, Inc. director Moncef Slaoui filed an initial Form 3 as a reporting person and disclosed that he currently holds no securities of the company. The filing shows total beneficial ownership of 0 shares of Vaxcyte common stock following the reported position and lists no purchase or sale transactions.
Vaxcyte, Inc. announced a planned change on its board of directors. On June 17, 2026, long‑serving director Jacks Lee retired from the board, with the company stating his retirement was not due to any disagreement or dispute. He will continue to support Vaxcyte under a consulting agreement focused on global strategic supply and manufacturing operations.
That same day, the board appointed Moncef Slaoui as a Class II independent director, effective immediately, with a term running until the 2028 annual stockholder meeting. He qualifies as an independent director under Nasdaq Rule 5605(a)(2), and the company reports no related‑party transactions requiring disclosure. Slaoui will be compensated under Vaxcyte’s non‑employee director compensation program, which currently sets the equivalent value of the annual equity grant for each director at $430,000, and he has entered into the company’s standard indemnification agreement.
Vaxcyte, Inc. director and CEO Grant Pickering reported a mix of stock option exercise and share sales in Common Stock on June 18, 2026. He exercised stock options for 225 shares at $1.79 per share and separately reported open-market sales totaling 24,461 shares at prices around $52.50 per share.
Two 1,000-share sales were attributed to children’s trusts that hold shares for his son and daughter, while 22,461 shares were sold from his direct holdings. After these transactions, Pickering holds 496,939 shares directly and 135,215 shares indirectly through trusts. The filing notes the sales were completed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.